drugset / Trial / NCT07601048
A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate the efficacy, and safety of HRS-7058 in KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
Timeline
- Start
- 2026-06
- Primary completion
- 2028-05
- Completion
- 2029-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fulzerasib | Small molecule | 600 mg | — |
| Comparator | Garsorasib | Unknown | 600 mg | — |
| Comparator | Glecirasib | Small molecule | 800 mg | — |
| Subject | HRS-7058 | Unknown | — | — |
Indications
No indication recorded.